ABSTRACT
Objective:To investigate the relationship between urinary glucose excretion, body mass index, and serum uric acid in type 2 diabetes mellitus, and to evaluate the association of interaction between uric glucose and body mass index on the risk of hyperuricemia.Methods:A total of 867 hospitalized patients with type 2 diabetes mellitus were included in this study. The height, weight, blood pressure and other general conditions were measured. 24-hour urine glucose quantification, glycolipid metabolism, and serum uric acid were collected. Multivariate linear regression analysis and multivariate logistic regression analysis were performed to determine the association of body mass index and urinary glucose with hyperuricemia.Results:After adjusting for age, sex, course of disease, blood pressure, HbA 1C, insulin, homeostasis model assessment for insulin resistance, fasting plasma glucose, 2 h postprandial blood glucose, total cholesterol, triglyceride, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol, creatinine, and glomerular filtration rate, body mass index was positively associated with serum uric acid( β=4.281, 95% CI 2.645-5.917, P<0.001), and 24-hour urine glucose was negatively associated with serum uric acid( β=-0.435, 95% CI -0.708--0.162, P=0.002). Body mass index is an independent risk factor of hyperuricemia( P<0.01). There was a significant interaction between urine glucose and body mass index(interaction P<0.05). In the low urine glucose group, obese patients displayed odds ratio of 2.203 for hyperuricemia compared with non-obese patients, whereas the odds ratio was not significant in the high urine glucose group.The associations between body mass index and hyperuricemia were stronger in participants with low urine glucose than in those with high urine glucose. Conclusion:Urinary glucose excretion can weaken the positive correlation between body mass index and serum uric acid, suggesting that promoting urinary glucose excretion may be an effective strategy to control serum uric acid levels in type 2 diabetes mellitus, especially in obese patients.
ABSTRACT
Objective To study that puerarin can prevent the renal glucose reabsorbtion process and promote urinary glucose excretion by inhibiting sodium-dependent glucose cotransporters 2 (SGLT2) to reduce plasma glucose in diabetes rats.Methods Molecular docking was carried out on puerarin and the obtained SGLT2 complexes through homology modeling method with dapagliflozin as positive control.Chinese hamster ovary (CHO) cells stably expressing human SGLT2 and [14C]-MethylD-glucopyranoside ([14C]-AMG) as the substrate were used in vitro for the transport assays and IC50 for SGLT2.The antihyperglycemic activity ofpuerarin was operated by oral glucose tolerance test (OGTT) and urinary glucose excretion (UGE) test in rats.Results Puerarin was identified as the substrate of SGLT2 through molecular docking,but the overall effect was not as strong asdapagliflozin.In vitro experiments showed that puerarin can strongly inhibit hSGLT2,the maximum effect was about 84％ with the half inhibitory concentration (IC50) of 0.40 mol/L.OGTT results showed that glucose inhibition rates of puerarin 10,30,60 and 120 mg/kg doses were 5.1％,6.5％,16％,and 22％ respectively,in a dose-dependent manner.In the UGE experiment,the urine sugar increased with the increase of puerarin dose.Compared with model group,the 30,60,and 120 mg/kg dose groups had significant difference (P ＜ 0.05 and 0.01).Conclusion Puerarin exhibited antiglycemic activity through inhibiting SGLT2 and was considered to be a new lead compound of SGLT2 inhibitors.
ABSTRACT
Objective To study the Tangniaole capsule assisted metformin on newly diagnosed type 2 diabetic patients influence blood glucose, urine glucose and insulin resistance level. Methods 80 patients with newly diagnosed type 2 diabetes mellitus were selected from January 2015 to October 2016 in our hospital. They were randomly divided into the control group and the experimental group, with 40 patients in each group. The control group was treated with metformin, and the experimental group was treated with metformin. Comparative analysis of blood and urine glucose and insulin in patients of the experimental group and the control level of resistance. Results After the corresponding treatment, the insulin resistance index in the experimental group was (2.31±0.51), and the insulin resistance index in the control group was (2.98±0.71). The insulin resistance index of the control group was significantly higher than that of the experimental group, with statistical difference (P<0.05). The fasting blood glucose level (7.31±1.02) nmol / Lin the experimental group was significantly lower than that in the control group (7.90±0.82)nmol / L, with statistical difference (P<0.05). Urine glucose levels of patients in the experimental group was significantly better than the control group, with statistical difference (P<0.05). Conclusion The application of Tangniaole capsule assisted with metformin in newly diagnosed type 2 diabetic patients in can largely reduce blood glucose and urine glucose and insulin resistance level, with further clinical promotion and application significance.
ABSTRACT
Objective To study the effects of positive urine glucose on maternal pregnancy.Methods A total of 1 338 pregnant women were tested urine glucose.On the basis of their urine-glucose level,two groups were devided:experimental,68 cases of posi-tive urine-glucose gravidas,control group,199 cases of negative urine-glucose gravidas.Analyze on the outcome of pregnancy of the two groups.Results Compared between positive group and control group,the incidence of died(abnormal)fetus,gestational hyper-tension,abnormal amniotic fluid,fetal distress,and fetal macrosomia were not statistically different(P >0.05),but the incidence of premature rupture of membranes was statistically different (P <0.05 ).Conclusion Positive glucose urine of gravidas might in-crease the risk of premature rupture of membranes,positive urine glucose detected during pregnancy should be highly valued.
ABSTRACT
Objective: Aiming at the target point of sodium-glucose transport protein (SGLT) inhibitors, to screen and estimate the hypoglycemic effects of novel glycoside derivatives by urine glucose testing methods. Methods: SD rats were ig administered with eight novel glycoside derivatives (30 mg/kg); The urine of rats was collected and the content of glucose was measured by hexokinase method in various periods. Also, the blood samples were obtained from tail vain of rats, the blood glucose was measured using blood glucose meter, and the glucose tolerance test of the active compounds was carried out. Results: In novel glycoside derivatives, N-glycoside TY702-1N and S-glycoside TY702-1S had less hypoglycemic effect, C-glycoside TY702-4C had more obvious effect of excreting glucose, and it has a dose-dependent manner in blood glucose and urine gluose. Conclusion: TY702-4C is a lead compound with good prospect in the research and development of new drug with more efficient and better pharmacokinetic characteristics.
ABSTRACT
Blood and urine specimens from 135 adult diabetic patients routinely visiting an outpatient diabetic clinic of Siriraj Hospital were collected and assayed for glucose levels. The results of negative, trace 1+, 2+, 3+ and 4+ by Diastix were associated with urinary glucose levels of 25.43, 161.57, 354.50, 776.67, 1598.18 and 4191.25 mg/dl and plasma glucose levels of 154.07, 193.93, 205.10, 216.11, 241.09 and 284.04 mg/dl respectively. Plasma glucose levels from 83-283 mg/dl were negative by Diastix and 100% of urine samples with plasma glucose levels above 300 mg/dl were positive by Diastix.